Medtronic Stock Competitors

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Risk & Volatility

Abbott Laboratories has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

72.1% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 79.6% of Medtronic shares are owned by institutional investors. 1.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Abbott Laboratories and Medtronic's net margins, return on equity and return on assets.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.4%. Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Abbott Laboratories has raised its dividend for 49 consecutive years and Medtronic has raised its dividend for 44 consecutive years.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Medtronic, as provided by MarketBeat.com.

Abbott Laboratories currently has a consensus target price of $129.4167, suggesting a potential upside of 4.06%. Medtronic has a consensus target price of $144.2381, suggesting a potential upside of 10.94%. Given Medtronic's higher possible upside, analysts clearly believe Medtronic is more favorable than Abbott Laboratories.

Valuation and Earnings

This table compares Abbott Laboratories and Medtronic's revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Medtronic.

Summary

Abbott Laboratories beats Medtronic on 9 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Insider and Institutional Ownership

79.6% of Medtronic shares are owned by institutional investors. Comparatively, 83.9% of Intuitive Surgical shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 0.8% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Medtronic has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Earnings & Valuation

This table compares Medtronic and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Intuitive Surgical.

Profitability

This table compares Medtronic and Intuitive Surgical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Medtronic and Intuitive Surgical, as reported by MarketBeat.com.

Medtronic currently has a consensus target price of $144.2381, suggesting a potential upside of 10.94%. Intuitive Surgical has a consensus target price of $952.8125, suggesting a potential downside of 8.68%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Medtronic on 8 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Institutional and Insider Ownership

72.6% of Stryker shares are held by institutional investors. Comparatively, 79.6% of Medtronic shares are held by institutional investors. 6.7% of Stryker shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Stryker and Medtronic, as provided by MarketBeat.com.

Stryker currently has a consensus price target of $286.4286, indicating a potential upside of 3.54%. Medtronic has a consensus price target of $144.2381, indicating a potential upside of 10.94%. Given Medtronic's stronger consensus rating and higher possible upside, analysts plainly believe Medtronic is more favorable than Stryker.

Volatility & Risk

Stryker has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Valuation and Earnings

This table compares Stryker and Medtronic's gross revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Stryker.

Profitability

This table compares Stryker and Medtronic's net margins, return on equity and return on assets.

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Stryker pays out 33.9% of its earnings in the form of a dividend. Stryker has raised its dividend for 1 consecutive years and Medtronic has raised its dividend for 44 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Medtronic beats Stryker on 10 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Earnings & Valuation

This table compares Medtronic and Edwards Lifesciences' top-line revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Edwards Lifesciences.

Risk and Volatility

Medtronic has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Medtronic and Edwards Lifesciences, as provided by MarketBeat.

Medtronic currently has a consensus target price of $144.2381, indicating a potential upside of 10.94%. Edwards Lifesciences has a consensus target price of $118.4375, indicating a potential downside of 1.36%. Given Medtronic's stronger consensus rating and higher possible upside, research analysts clearly believe Medtronic is more favorable than Edwards Lifesciences.

Institutional and Insider Ownership

79.6% of Medtronic shares are owned by institutional investors. Comparatively, 80.1% of Edwards Lifesciences shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 1.4% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Medtronic and Edwards Lifesciences' net margins, return on equity and return on assets.

Summary

Edwards Lifesciences beats Medtronic on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Profitability

This table compares Medtronic and Becton, Dickinson and's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Medtronic and Becton, Dickinson and, as reported by MarketBeat.com.

Medtronic currently has a consensus target price of $144.2381, suggesting a potential upside of 10.94%. Becton, Dickinson and has a consensus target price of $273.6250, suggesting a potential upside of 8.08%. Given Medtronic's stronger consensus rating and higher possible upside, equities research analysts clearly believe Medtronic is more favorable than Becton, Dickinson and.

Institutional & Insider Ownership

79.6% of Medtronic shares are held by institutional investors. Comparatively, 84.3% of Becton, Dickinson and shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Medtronic and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Becton, Dickinson and.

Dividends

Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. Medtronic has increased its dividend for 44 consecutive years and Becton, Dickinson and has increased its dividend for 50 consecutive years.

Volatility and Risk

Medtronic has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Medtronic beats Becton, Dickinson and on 13 of the 17 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Boston Scientific and Medtronic's gross revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Boston Scientific.

Profitability

This table compares Boston Scientific and Medtronic's net margins, return on equity and return on assets.

Risk and Volatility

Boston Scientific has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Boston Scientific and Medtronic, as provided by MarketBeat.

Boston Scientific currently has a consensus price target of $49.1338, suggesting a potential upside of 9.92%. Medtronic has a consensus price target of $144.2381, suggesting a potential upside of 10.94%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than Boston Scientific.

Insider and Institutional Ownership

89.8% of Boston Scientific shares are held by institutional investors. Comparatively, 79.6% of Medtronic shares are held by institutional investors. 0.7% of Boston Scientific shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Medtronic beats Boston Scientific on 7 of the 13 factors compared between the two stocks.